Ekso Bionics (EKSO) Registration Filing summary

Company overview and business model

• Designs, develops, and markets exoskeleton products to augment human strength, endurance, and mobility, primarily targeting healthcare for physical rehabilitation and mobility impairments.

• Majority of sales come from Enterprise Health products for neurorehabilitation in clinical settings, with additional offerings for individual users.

• Continues to explore business development initiatives to drive growth and long-term value in existing markets.

Financial performance and metrics

• Historically has not achieved profitability and has relied on external equity and debt financings to fund operations.

• As of December 31, 2024, had $4.1 million available for future offerings under an At The Market (ATM) Agreement.

• Recent gross proceeds of approximately $4.2 million were raised from warrant exercises at $0.4239 per share.

• The latest audit report includes a going concern explanatory paragraph, highlighting substantial doubt about the ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by the selling stockholder; proceeds from recent warrant exercises were previously received.